secwatch.observer — SEC 8-K summary
======================================

Issuer:     Prime Medicine, Inc. (PRME)
CIK:        0001894562
Form:       8-K
Filed at:   2026-11-10T21:06:42+00:00
Accession:  0001628280-26-072713
Event type: other_material
Sentiment:  neutral
Materiality: 0.45
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Prime Medicine pegs Sept 30 cash at ~$61.2M preliminary, excluding $13.7M restricted
--------------------------------------------------------------------------------

- Preliminary unaudited cash, cash equivalents and short-term investments of approximately $61.2 million as of September 30, 2026; restricted cash of ~$13.7 million excluded.
- Company has not completed its quarter-end close for Q3 2026; warns actual results may differ materially from these management estimates.
- PricewaterhouseCoopers has not audited, reviewed, examined or compiled the preliminary figures and expresses no assurance on them.
- Complete results will be reported in the Form 10-Q for the quarter ended September 30, 2026; no duty to update the estimates.
- Updated November 2026 corporate presentation posted to the investor site; the Exhibit 99.1 text supplied here is truncated, so deck contents could not be verified.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1894562/000162828026072713/0001628280-26-072713-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1894562/000162828026072713/prme-20261110.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-072713

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer